Skip to main content
NCD 190.7 · version 1

NCD 190.7: Human Tumor Stem Cell Drug Sensitivity Assays

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.7

Benefit category
Diagnostic Laboratory Tests
Effective date
07/01/1996
Transmittal
Transmittal 88
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3

TL;DR

NCD 190.7 sets Medicare's national policy for human tumor stem cell drug sensitivity assays under the benefit category "Diagnostic Laboratory Tests", effective 07/01/1996. Human tumor drug sensitivity assays are considered experimental, and therefore, not covered under Medicare at this time. It has been revised once since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

Human tumor stem cell drug sensitivity assays involve exposure of human tumor stem cell colonies grown in tissue culture to anticancer drugs and observing for cytotoxic effects. Their purpose is to screen potential anticancer drugs and predict the effects of these drugs on tumors of individual patients, to allow the selection of the most effective drug or drugs for that patient.

The Fluorescent Cytoprint Assay, a miniaturized organ culture system for cancer chemosensitivity testing, allows for qualitative visual estimation of cell kill using low power microscopy and a noncytotoxic fluoresence probe for cell viability.

Indications and limitations of coverage

Human tumor drug sensitivity assays are considered experimental, and therefore, not covered under Medicare at this time.

The clinical application of the assay, based on testing in tumor microorgans rather than in clones derived from single cells, is considered experimental, and therefore, not covered under Medicare at this time.

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.7 version 1. View the original on cms.gov.

Local policies that build on this NCD

2 active Local Coverage Determinations cite NCD 190.7 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

  • L34554 In Vitro Chemosensitivity & Chemoresistance Assays · Palmetto GBA
  • L37628 In Vitro Chemosensitivity & Chemoresistance Assays · Noridian Healthcare Solutions, LLC

How MACs bill NCD 190.7

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 2 current articles in the Medicare Coverage Database name NCD 190.7, from 1 contractor. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

Contractors with articles that implement NCD 190.7
ContractorArticles
Noridian Healthcare Solutions, LLCA56071, A55215

A56071: Billing and Coding: In Vitro Chemosensitivity & Chemoresistance Assays

Billing and Coding, effective 2025-10-16 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

No covered diagnosis list; 3 procedure codes: 0083U, 84999, 89240. Local policy: L37628 In Vitro Chemosensitivity & Chemoresistance Assays. Check a diagnosis for 0083U.

A55215: Billing and Coding: Incident To Clarification for OPPS and CAH Outpatient

Billing and Coding, effective 2025-09-25 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

No covered diagnosis list.

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 190.7, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00044N Human Tumor Assay Systems (New, Closed)

Revision history

07/1996 - Clarified that the clinical application of fluorescent cytoprint assay is experimental and not covered. Effective date NA. (TN 88)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.7

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.7

What does NCD 190.7 cover?

Human tumor drug sensitivity assays are considered experimental, and therefore, not covered under Medicare at this time. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.7 take effect?

The current version (1) is effective 07/01/1996, published in transmittal 88. This is the only published version.

Does a Local Coverage Determination override NCD 190.7?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.